Study of Dose-dense Adriamycin Plus Cytoxan (AC) Followed by Either ABI-007 (Abraxane) or Taxol With Bevacizumab as Adjuvant Therapy for Patients With Breast Cancer
Condition: Breast Cancer
MeSH terms: Breast Neoplasms
Intervention: Adriamycin and Cytoxan (AC); ABI-007; Taxol; Bevacizumab; pegfilgrastim
Intervention description: Adriamycin (doxorubicin) and Cytoxan (cyclophosphamide) make up the chemotherapy regimen known as AC. Adriamycin 60 mg/m^2 intravenous, plus Cytoxan 600 mg/m^2 intravenous on Day 1 of each of four 2-week cycles (weeks 1-8).; 260 mg/m^2 IV on day 1 of each of four 2-week cycle, representing treatment cycles 5-8 (weeks 9-16); 175 mg/m^2 intravenously (IV) on day 1 of each of four 2-week cycle, representing treatment cycles 5-8 (weeks 9-16); 10 mg/kg on day 1 of each of eight 2-week cycles (weeks 9-16), then 15 mg/kg on day 1 of each of ten three-week cycles (weeks 17-46).; 6 mg subcutaneous (SC) on day 2 for each of the first four 2-week cycles (weeks 1-8). Pegfilgrastim 6 mg SC was administered on day 2 of cycles 6-8 (weeks 11-16) during taxane treatment only if necessary.
Intervention MeSH terms: Paclitaxel; Cyclophosphamide; Bevacizumab; Doxorubicin; Liposomal doxorubicin; Albumin-Bound Paclitaxel
Phase: Phase 2
Study type: Interventional
Primary purpose: Treatment
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: None (Open Label)
Enrollment: 197.0
Sex: Female
Minimum age: 18 Years
Maximum age: 70 Years
Healthy volunteers: No
Keywords: Adjuvant therapy; Bevacizumab; Abraxane; Early stage breast cancer

Summary:

      The primary objective of this study was to compare the safety of dose-dense ABI-007
      (Abraxane) 260 mg/m^2 or Taxol 175 mg/m^2 given every 2 weeks following dose-dense Adriamycin
      plus Cytoxan (AC) chemotherapy. Bevacizumab was administered at 10 mg/kg every 2 weeks
      throughout chemotherapy, and then at 15 mg/kg every 3 weeks following chemotherapy.
    

Eligibility criteria:

        Inclusion Criteria:

        A patient was eligible for inclusion in this study only if all of the following criteria
        were met:

          1. Female, age greater than or equal to 18 to less than or equal to 70 years old.

          2. Estrogen receptor (ER) and progesterone receptor (PR) status have been determined.

          3. Operable, histologically confirmed adenocarcinoma of the breast

          4. Must have met 1 of the following criteria:

               -  T1-3, N1-3, M0, regardless of ER or PR status.

               -  T > 2 cm, N0, M0 (T2-3N0M0), regardless of ER or PR status.

               -  T > 1 cm, N0, M0 (T1cN0M0) and both ER and PR negative

               -  T > 1 cm, N0, M0, ER or PR positive and grade 3

          5. Patients with one sentinel lymph node metastasis 0.2-2 mm in size were not required to
             undergo completion axillary dissection unless only 1 sentinel lymph node was examined.
             This completion axillary dissection was optional if 1 out of 2 or more sentinel lymph
             nodes was positive for a micrometastasis. Therefore if 1 of 1 sentinel lymph node was
             positive for micrometastasis(0.2-2 mm), then a completion axillary dissection was
             required.

          6. Patients with more than one sentinel node micrometastasis or 1 node with a
             micrometastasis > 2 mm and/or T3 disease must have undergone completion, standard
             axillary dissection. -Note: the following were not eligible-

             T1b,c,N0M0 and ER or PR positive and grade 1 or 2 Tx tumors (regardless of nodal
             status) T4 disease [i.e., patients with fixed tumors, peau d'orange skin changes, skin
             ulcerations, or inflammatory changes

               -  Note: Sentinel lymph node micrometastasis < 0.2 mm in considered N0 disease

          7. Negative surgical margins on lumpectomy or mastectomy specimen (no ink on invasive
             cancer and no ink on ductal carcinoma in situ [DCIS]).

          8. Eastern Cooperative Oncology Group (ECOG) performance status 0-1

          9. Normal electrocardiogram (ECG, as assessed by the investigator).

         10. No pre-existing peripheral neuropathy.

         11. It had not been longer than 84 days since the date of definitive surgery (eg,
             mastectomy or in the case of a breast-sparing procedure, axillary dissection).

         12. Laboratory values were to be as follows:

               -  White blood cell count: > or equal to 3,000/mm^3

               -  Absolute neutrophil count:> or equal to 1,500/mm^3

               -  Platelets:> or equal to 100,000/mm^3

               -  Hemoglobin: > or equal to 8g/dL

               -  Bilirubin:< or equal to the institution's ULN

               -  Creatinine: < or equal to 1.7 mg/dL

               -  Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) and alkaline
                  phosphatase could be up to 2.5 times the institutional ULN.

         13. All staging studies including physical exam, chest x-ray, and bone scan had to show no
             evidence of metastatic disease, including suspicious lymphadenopathy or skin nodules
             on physical exam. A chest x-ray and bone scan were mandatory; however, all other
             staging studies were at the treating physician's discretion. Any other staging test
             (eg, Computed Tomography [CT] scans, magnetic resonance imaging [MRI] studies,
             ultrasound of abdomen, Positron Emission Tomography [PET] scans must have been
             negative for metastatic disease. An abdominal CT scan or PET scan was mandatory for
             patients with liver function tests elevated above the upper limit of normal (ULN) to
             rule out metastatic disease. If the patient had a staging PET scan then a bone scan
             was not necessary, but a chest x-ray was required.

         14. Patient had a negative serum pregnancy test < or equal to 14 days of the first dose of
             study drug (patients of childbearing potential).

         15. If fertile, patient had agreed to us an acceptable method of birth control to avoid
             pregnancy [Note: oral contraceptives were not allowed] for the duration of
             chemotherapy and hormonal therapy and for 6 months thereafter.

         16. If obese, a patient must have been treated with doses calculated using his/her actual
             body surface area (BSA) (the physician must have been comfortable treating at the full
             BSA dose regardless of BSA).

         17. Patient had signed a Patient Informed Consent Form.

        Exclusion Criteria:

        A patient was not eligible for inclusion in this study if any of the following criteria
        applied:

          1. Patients with HER-2 positive breast cancer (IHC 3+ or FISH +) who were eligible for
             adjuvant Herceptin therapy.

          2. Stage IV breast cancer (M1 disease on TNM staging system).

          3. Prior anthracycline, anthracenedione (mitoxantrone), or taxane therapy

          4. Neoadjuvant therapy for this breast cancer.

          5. Previous invasive cancers if treated < 5 years prior to entering this study, except
             basal or squamous cell carcinoma of the skin or carcinoma in situ of the cervix; the
             latter were not required to have occurred more than 5 years prior to study entry.

          6. Prior invasive breast cancer if diagnosed < 5 years prior to entering study. Patients
             must have finished adjuvant hormonal therapy prior to registration. Patients with
             prior DCIS are eligible. Patients with DCIS who were treated with tamoxifen must have
             finished tamoxifen prior to registration.

          7. Serious medical illness, other than that treated by this study, which would limit
             survival to < 4 years, or psychiatric condition that would prevent informed consent
             and compliance with study treatment.

          8. Uncontrolled or severe cardiovascular disease including recent (< or equal to 12
             months) myocardial infarction or unstable angina.

          9. Active uncontrolled bacterial, viral (including clinically defined Acquired Immune
             Deficiency Syndrome [AIDS]), or fungal infection.

         10. Patients with active or chronic hepatitis with abnormal liver function tests (LFTs) or
             patients who were known to be HIV positive.

         11. Uncontrolled disease such as uncontrolled diabetes.

         12. Any prior history of hypertensive crisis or hypertensive encephalopathy.

         13. Any known central nervous system (CNS) disease.

         14. Known hypersensitivity to any component of bevacizumab.

         15. No history of cerebrovascular accident or transient ischemic attack at any time.

         16. Active symptomatic vascular disease, e.g., aortic aneurysm or aortic dissection, and
             no peripheral vascular disease, e.g., claudication, within six months of study entry.

         17. No major surgical procedure, open biopsy, or significant traumatic injury within 28
             days and no core biopsy or minor surgical procedure (excluding placement of a vascular
             access device) within seven days of study entry. No anticipated need for major
             surgical procedure during the course of study.

         18. No history of abdominal fistula, gastrointestinal perforation, or intra- abdominal
             process within six months of study entry.

         19. No serious non-healing wound, ulcer, or bone fracture.

         20. No proteinuria at screening as demonstrated by urine protein: urine creatinine (UPC)
             ratio of > or equal to 1.0 or urine dipstick for proteinuria > or equal to 2+
             (patients discovered to have > or equal to 2+ proteinuria on dipstick urinalysis at
             baseline should have undergone a 24 hour urine collection and must have demonstrated <
             or equal to 1g of protein in 24 hours to be eligible).

         21. Inadequately controlled hypertension (defined as systolic blood pressure > 150 mmHg
             and /or diastolic blood pressure> 100 mmHg on antihypertensive medications) or New
             York Heart Association (NYHA) Grade 2 or greater congestive heart failure.

         22. History or coagulopathy, bleeding diathesis, therapeutic anticoagulation other than
             low dose or chronic acetyl salicylic acid (ASA)> or equal to 325 mg. per day. Low dose
             coumadin for anticoagulation of venous access device or low dose molecular weight
             heparin (LMWH) for deep vein thrombosis prophylaxis or low dose (325 mg or less) ASA
             prophylaxis are allowed, but are best avoided if the treating physician feels it is
             safe to do so.

         23. Left Ventricular Ejection Fraction (LVEF) on cardiac echocardiography (ECHO) < 50% (or
             institutional lower limit of normal [LLN]) and > or equal to 74%. LVEF of greater than
             75% at baseline should have been re- reviewed and/or the test repeated as it could be
             falsely elevated.

         24. Patients who were receiving concurrent immunotherapy.

         25. A history of other malignancy within the last 5 years, which could affect the
             diagnosis or assessment of breast cancer recurrence or which could shorten a patient's
             survival.

         26. Patient had had an organ allograft.

         27. Patient was pregnant or breastfeeding.

         28. Patient was unable to comply with requirements of study.

         29. Patient was receiving any other investigational drugs.